Nidda Sets Price For Stada Squeeze-Out
Bain Capital And Cinven Vehicle Set To Take Full Control
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.
You may also be interested in...
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Stada’s owner has revealed plans to squeeze out the German firm’s remaining minority shareholders.
Bain Capital and Cinven will hold 93.61% of Stada’s share capital and voting rights after completing their public delisting tender offer for remaining shares in the German company, according to the two firms’ Nidda Healthcare holding company.